Industrial Processes in Biomedicinal Product Development
A growing industrial site
LFB BIOMANUFACTURING has acquired a 3rd production unit dedicated specifically to the production of molecules requiring specific viral safety and which has been put to good use by many customers for the manufacture of anti-COVID therapies.
On 14 June 2024, LFB BIOMANUFACTURING laid down the foundation stone for the extension of its bioproduction site in Alès. This €20 million investment, financed by the French government via its “France 2030” plan, will provide customers with doubled production volumes thanks to two new 2,000-litre bioreactors. This expansion is also slated to house development and analytical services, and a storage warehouse for raw materials used in production.
